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1. Introduction
Glucagon-like peptide (GLP-1) is derived from the processing of the proglucagon gene. This
peptide has diverse biological activities affecting peripheral tissues and the central nervous
system. Thus, for example, GLP-1 stimulates pancreas insulin secretion in a glucose-depend‐
ent manner after eating, hence its denomination as an “incretin”. GLP-1 has also been con‐
sidered an anorexigenic peptide, while also reducing cerebral glucose metabolism in the
human hypothalamus and brain stem. These GLP-1 actions in the pancreas and central nerv‐
ous system are achieved through GLP-1 receptors (GLP-1R) that share the same gene se‐
quence in both tissues. In short, GLP-1 is an antidiabetogenic agent due to its action in the
pancreas while acting in hypothalamic areas, helping to generate a state of satiety. Interest‐
ingly, GLP-1/exendin-4 administration in obese Zucker rats, which also develop insulin re‐
sistance, hyperinsulinemia and hyperlipidemia, reduces food intake and induced weight
loss, which applies to lean rats, too.
The mid 20th century recorded the first indications that the hypothalamus plays a major role
in feeding behaviour and energy homeostasis, whereby the electrical stimulation of the ven‐
tromedial hypothalamus (VMH) suppresses food intake, and the bilateral lesions of these
structures induce hyperphagia and obesity. The VMH was therefore called the satiety cen‐
tre. In contrast, alterations in the lateral hypothalamic area (LH) induced the opposite set of
responses, and the LH was hence called the hunger centre. At least two kinds of glucose sen‐
sor neurons have been described in the brain: glucose-excited neurons are located mainly in
the VMH and are excited by increased glucose levels in the extracellular space, while glu‐
cose-inhibited neurons (mainly present in the LH) are excited by decreases in glucose con‐
centrations. A direct relationship has also been established between the regulation of food
intake and energy homeostasis and hypothalamic metabolic sensor activities.
© 2013 Hurtado et al.; licensee InTech. This is an open access article distributed under the terms of the
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Both AMP-activated protein kinase (AMPK) and the mammalian target of rapamycin
(mTOR) and its downstream target p70 ribosomal protein S6 Kinase 1 (S6K1) contribute to
detecting cellular energy and integrate nutrient and hormonal signals in order to maintain
energy homeostasis in the organism. Thus, the Ser/Thr kinase AMPK is activated during en‐
ergy depletion, when the AMP/ATP ratio increases and triggers a large number of down‐
stream effectors by stimulating ATP-generating catabolic pathways and inhibiting anabolic
pathways in order to restore the energy balance. Specifically, it has been reported that fast‐
ing increases, and re-feeding decreases, AMPK activity in several hypothalamic areas. Like‐
wise, the hypothalamic mTOR/S6K1 pathway has also been involved in the control of
feeding and in the regulation of energy balances. Thus, mTOR is activated by glucose and
amino acids and, therefore, hypothalamic AMPK and mTOR/S6K1 respond to changes in
glucose and other nutrients in the opposite way, and their effects on the regulation of food
intake may overlap. Our recent results indicate that AMPK and S6K1 are functionally ex‐
pressed in the VMH and LH areas, with differential activation in response to glucose fluctu‐
ations, in both in vitro models of hypothalamic organotypic slice cultures and animals in
response to fasting and re-feeding, as well as in Zucker obese rats with a lower activation
degree of hypothalamic AMPK in response to fasting.
In addition, we have reported that GLP-1/exendin-4 treatment inhibits the activities of
AMPK and S6K1 when the activation of these protein kinases peak in both the VMH and LH
areas. In pathophysiological situations, as occurs in Zucker obese rats, exendin-4 seems to
act as a compensator for the variations in AMPK activity produced either by oscillations in
glucose levels or by pathologies such as obesity or episodes of hyperinsulinemia.
In conclusion, it seems that GLP-1/exendin-4 acts in the VMH and LH, modulating the acti‐
vation status of AMPK and S6K1 in response to glucose fluctuations, helping to improve
pathophysiological states such as obesity and insulin resistance. The effects of these peptides
in the hypothalamus are mediated through the activation of PKA, PKC and PI3K, as well as
the phosphatase PP2.
2. Glucagon-like peptide-1: Dual role as an incretin and anorexigenic
peptide
Glucagon and related peptides constitute a family derived from the proglucagon molecule,
which is identical in sequence in the pancreas, intestine and brain [1], although post-transla‐
tional processing of the precursor yields different products in these organs [2]. (Figure 1)
In gut L-cells, the C–terminal portion of proglucagon is predominantly processed to gluca‐
gon-like peptide-1 (GLP-1) and GLP-2. Further processing of GLP-1 in these cells produces
the amidated and truncated forms of the peptide: GLP-1 [7-36] amide, GLP-1 [7-37] and
GLP-1 [1-36] amide, with the first two being the biologically active forms, which are cited in
the rest of the test as GLP-1. Although the truncated forms of GLP-1 are reported to have
strong incretin activity, it is currently known that they are also important in the functioning
of other peripheral tissues and the central nervous system. Both forms of the peptide are in‐
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distinguishable in their ability to produce biological effects through GLP-1 receptors located
in pancreatic cells [3], gastric glands [4] and in adipocytes [5], lung [6] and brain [7-10].
Figure 1. Posttranslational processing of preproglucagon. GLP: Glucagon-like peptide; GRPP: Glicentin-related pancre‐
atic peptide; IP: Intermediate peptide; MPGF: the major proglucagon fragment; PS: Signal peptide.
In addition, GLP-1 and its own receptors are synthesized in the same brain regions, strongly
supporting the actions of this peptide on the CNS. Thus, the perfusion of several brain nu‐
clei with GLP-1 produces a selective release of neurotransmitters [11, 12], and the central
and peripheral administration of this peptide inhibits food and drink intake [13-15]. The co-
expression of GLP-1R, glucokinase, and glucose transporter protein 2 (GLUT-2) in the neu‐
rons involved in the control of food intake suggests that these cells may play a role in
glucose sensing in the brain [14, 16-19]. Furthermore, GLP-1 has beneficial cardiovascular ef‐
fects in humans by lowering blood pressure and improving myocardial function [20, 21], al‐
though in rats this peptide significantly increases arterial blood pressure and heart rate [22,
23]. Interestingly, GLP-1 has proliferative and antiapoptotic actions on pancreatic β-cells [24,
25], and has neurotrophic and neuroprotective features [21]. Considering the functions of
GLP-1, its exendin-4 analogue is used in the treatment of type 2 diabetes [26].
Within the multiple functions of GLP-1, we have selected two important ones, namely, an
incretin and an anorexigenic peptide.
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2.1. GLP-1 actions as incretin hormone
The proposals made in 1906 by Moore et al. [27] on the antidiabetogenic effect of intestinal
factors, and in 1929 by Zung & La Barre [28] on the release of a substance from intestinal
mucosa with properties to decrease glycaemia, signalled the start of the development of the
incretin concept and the study of the relationships between the gut and the endocrine pan‐
creas. However, for many years these suggestions were ignored, until the development of
radioimmunoassays, when Elrich et al. [29] demonstrated that the insulin secretion response
to an oral glucose overload was greater to that obtained after intravenous perfusion with the
same amount of glucose. This lends support to the belief that substances from the intestine
were involved in the postprandial control of insulin secretion, which was referred to accord‐
ingly as the incretin effect. It is accepted that 20% to 60% of the increase in postprandial in‐
sulin secretion is due to this effect; with the broad oscillation being explained by the amount
and composition of food intake.
The functional relationships between the intestine and the pancreatic islet were named by
Unger and Eisentraut in 1969 [30] as the enteroinsular axis, while the criteria formulated by
Creutzfeldt [31] considered a molecule to be incretin when it is secreted in response to nu‐
trients, and that physiological concentrations increased the secretion of insulin in the pres‐
ence of high glucose concentrations.
The first peptide described with incretin activity was the gastric inhibitory polypeptide
(GIP) that went on to be referred to also as the glucose-dependent insulinotropic polypep‐
tide GIP). Thereafter, the observation of incretin activity after the inactivation of GIP sug‐
gested the existence of other molecules with an incretin effect. Thus, in experimental models
where GIP was blocked by its own antibodies 50-80% of incretin activity was still observed.
We now know that GLP-1 has a greater incretin effect than GIP, being considered the most
powerful incretin molecule of all those known. In other words, a molecule with incretin ac‐
tivity may be defined as a hormone of intestinal origin that potentiates the secretion of insu‐
lin after the oral ingestion of nutrients. Knowledge of incretins has been very useful for a
better understanding of certain pathophysiological entities [32]. In 1986, Nauck et al. [33]
first documented a reduced incretin effect in patients, with type 2 diabetes. It is important to
note that Nauck et al. described this reduced effect with GIP and not with GLP-1, because at
that time GIP was the only incretin known. However, a year later [34], GLP-1 was identified
as an incretin hormone and shown to be more effective than GIP to stimulate insulin secre‐
tion on a molar basis and at an equivalent level of glucose concentration [35]. Both in non-
diabetic and type 2 diabetic subjects, GLP-1 was more effective than GIP at enhancing
insulin secretion and lowering glucagon concentrations [36].
The recognition that native GLP-1 is quickly degraded by the protease dipeptidyl peptidase
IV (DPP-4) led to the development of GLP-1 agonists that are resistant to this enzyme [37].
The degradation by DPP-4 of exenatide and liraglutide and DPP-4 inhibitors (sitagliptin,
saxagliptin, vildagliptin and linagliptin) currently represents an effective therapeutic option
for patients with type 2 diabetes. Furthermore, several agents have been developed in recent
years, including longer acting DPP-4 resistant GLP-1 agonists.
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In addition, many biological effects of GLP-1, other than incretin actions, have been reported
in recent decades, representing a good tool for several therapeutic treatments. These GLP-1
effects include properties such as an anorexic peptide, beneficial cardiovascular actions in
humans, increased pulmonary surfactant formation in human and experimental animals,
pancreatic islet neogenesis and proliferative and antiapoptotic actions. GLP-1 receptors are
also widely expressed in the brain [9, 10], where their agonists produce a selective release of
neurotransmitters [11, 12] and increase GLP-1 receptor expression in glia after a mechanical
lesion of the rat brain has been reported [38]. Accordingly pre-clinical data suggest a neuro‐
protective/neurotrophic function of GLP-1, and some authors have proposed that this pep‐
tide may have a positive potential role for reversing neurodegenerative disorders [21].
2.2. GLP-1 actions in the control of food intake
A number of peptide hormones, previously thought to be specific to the gastroenteropancre‐
atic system and later found also in the mammalian brain, have been shown to modulate ap‐
petite, energy homeostasis and body weight. They have these physiological effects together
with other neuropeptides, such as neuropeptide Y (NPY), opioid peptides, galanin, vaso‐
pressin, and GHRH. Peptide Y (Y3-36) is also released from the gastrointestinal tract post‐
prandially, and acts on the NPY Y2 receptor in the arcuate nucleus to inhibit feeding, with a
long–term effect [39]. Conversely, other satiety signals induced by gut-brain peptides such
as GLP-1 [13-15], GLP-2 [40] and cholecystokinin produced a short-term effect, while insulin
and leptin [41] inhibit the appetite by increasing the formation of pro-opiomelanocortin
(POMC) and reducing NPY action. In addition, ghrelin, a peptide released by the stomach,
is stimulated before meals to facilitate NPY action.
GLP-1 and GLP-2 significantly modify feeding behaviour. The intracerebroventricular (icv)
or subcutaneous administration (sc) of GLP-1 produced a marked reduction in food intake
and water ingestion [13-15]. Exendin-4 proved also to be a potent agonist of GLP-1 by de‐
creasing both food and water intake in a dose-dependent manner. Pre-treatment with exen‐
din [9-39], an inhibitor of the GLP-1 receptor, reversed the inhibitory effects of GLP-1 and
exendin-4. These findings suggest that GLP-1 may modulate both food and water intake
through either a central or peripheral mechanism. Similar results have been found in hu‐
mans when the peptide was administered in the periphery [42]. After the subcutaneous ad‐
ministration of GLP-1, it could enter the brain by binding to blood–brain–barrier-free organs
such as the subfornical organ and the area postrema [43], or through the choroid plexus,
which has a high density of GLP-1 receptors [17].
Several observations suggest a possible action of GLP-1 on thirst-regulatory mechanisms,
since GLP-1R mRNA has been located in brain areas related to the control of thirst, such as
the preoptic area, glial cells lining the third ventricle and, especially, the neurons of the
PVN, which is a key station for water balance regulation through the antidiuretic effects of
vasopressin released by its projection to the neurohypophysis [44]. In addition, the icv ad‐
ministration of GLP-1 significantly increases the circulating levels of vasopressin, and the
colocalization of the mRNA of the GLP-1 receptor, and vasopressin has been found in the
neurons of the PVN [45].
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The control of feeding behaviour by GLP-1 and exendin-4 has been explored in Zucker
obese rats, resulting in a reduction in food intake, with exendin-4 being much more potent
than GLP-1. The long-term sc administration of exendin-4 decreased daily food intake and
practically blocked weight gain in obese rats. These observations highlight the potential use‐
fulness of exendin-4 as a tool for treating obesity and/or diabetes. Both GLP-1 and exendin-4
control blood glucose through the stimulation of glucose-dependent insulin secretion, the
inhibition of glucagon secretion, and delayed gastric emptying [34, 46, 47], which facilitate
the decrease in blood glucose in type 1 and type 2 diabetic patients [48]. In the light of these
results, different N-terminal substituted GLP-1 analogues resistant to DPP-IV have recently
been developed. These resistant analogues have a prolonged metabolic stability in vivo and
improved biological activity, which is of great interest in the treatment of type 2 diabetes
and/or obesity.
On the other hand, the icv administration of GLP-2 to mice and rats produced a marked de‐
crease in food intake but not in water ingestion [43]. Surprisingly, this effect was avoided by
the administration of exendin [9-39], an antagonist of GLP-1.
3. Importance of the VMH and LH in the control of food intake
In recent years, researchers have been focusing on the relationship between gut hormones
and the brain areas controlling appetite, ingestion, food reward and body weight [49, 50].
Both gut and brain are considered the main organs responsible for controlling body weight.
The hypothalamus is the focus of many of the peripheral signals and neural pathways that
control energy homeostasis and body weight. However, new evidence has been forthcoming
in recent years to suggest that human food intake is also controlled by other areas in the cen‐
tral nervous system, such as subcortical and cortical areas.
The hypothalamus regulates body weight by precisely balancing the intake of food, energy
expenditure and body fat tissue. The role of the hypothalamus in regulating food intake and
body weight was established in 1940 [51] through the classical experiments by Hetherington
and Ranson. They placed bilateral electrolytic lesions in a vast region of the hypothalamus,
occupied by the dorsomedial and ventromedial areas, the arcuate nucleus, the fornix and a
portion of the lateral hypothalamic area (without disturbing the pituitary gland). The results
were a marked adiposity characterized by a doubling of body weight and a huge increase in
body lipids. A few years later, Anand and Brobeck [52] continued these experiments in
greater detail, demonstrating that lesions of the lateral hypothalamus at the level adjacent to
the ventromedial nucleus caused loss of appetite, inanition, and even death by starvation.
Thus, the lateral hypothalamic area acted as a “feeding centre” and the ventromedial nu‐
cleus as a “satiety centre”. Since then, it has been established that the “dual centre model”
regulates feeding [53], that the proposed lesioning of the VMH increases appetite, while
stimulating the VMH decreases it. By contrast, lesioning or stimulating the LH decreases or
induces appetite, respectively.
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The dual control theory of feeding is based on the homeostatic view of hunger and satiety,
together with the consideration of glucose not only as a metabolic fuel, but also as a signal‐
ling molecule, and the existence of specialized neurons containing glucose sensors that acti‐
vate or inhibit feeding when blood glucose levels change. A fall in glucose would activate
the LH and, consequently, give rise to hunger. Hunger leads to the consumption of food and
thus to an elevation of glucose levels that would activate the VMH, leading to a feeling of
satiety that will stop the feeding, and eventually glucose levels would fall again.
Over the last 25 years, there has been a dramatic increase in studies on the hypothalamus.
Knowledge of the hypothalamus has only recently evolved from anatomical concepts (nu‐
clei, ‘areas’ and fibre tracts) to neurochemicals (characterizing the distributions of neuropep‐
tides and transmitters and their receptors), focusing on the modulation of feeding behaviour
and energy expenditure. We are now beginning to reach the stage of functionally under‐
standing the molecular mechanisms, defining exactly which neuronal populations respond
to specific nutritional and related signals, and how they pass on that information. At least 25
transmitters have been suggested to play key roles in feeding behaviour [54]. Accordingly,
the dorsomedial and paraventricular regions are important within the hypothalamus, along
with the well-established VMH and LH [55]. The VMH, which consists of the ventromedial
and arcuate nuclei, respectively, is a key region for integrating the peripheral signals of nu‐
trient status and adiposity. The arcuate nucleus contains neurons with NPY/AgRP and
POMC, which have opposing effects on energy homeostasis. Thus, NPY increases food in‐
take and activates energy sparing mechanisms, while melanocortins decrease food intake
and increase energy expenditure [56]. On the other hand, the LH, the classical “feeding cen‐
tre”, is a heterogeneous area that receives a multitude of neuronal inputs from many areas
known to be important in the regulation of energy homeostasis: LH encompassing neurons
and terminals containing orexigenic peptides. Basically, the LH contains two distinct neuro‐
nal cell populations that regulate feeding behaviour: containing hypocretin/orexin [57, 58]
and a melanin-concentrating hormone (MCH) [59] (Figure 2).
In addition to its response to circulating peptides and hormones that reflect energy status,
the brain, and specifically the hypothalamus, also senses and responds to changes in blood
glucose levels [14, 16, 18, 19, 60]. There are several areas in the brain acting as a glucose sen‐
sor. Examples of these are the hypothalamus [60, 61], nucleus solitarius [62] and amygdala
[63]. The glucose sensing neurons located in these areas monitor energy status and initiate
the responses to maintain glucose and energy homeostasis. Besides the brain glucose sen‐
sors, there are also glucose sensors located in peripheral tissues including the intestine [64],
the carotid body [65] and mesenteric veins [66]. In fact, glucose sensors in the hypothalamus
were first discovered in the VMH and LH [57, 58]. Moreover, interstitial glucose levels in the
VMH and LH vary with blood glucose concentration [67], and these changes in glucose have
been postulated to trigger meal initiation. Since glucose is the brain’s primary fuel, it should
respond to a severe glucose deficiency. In this way, VMH glucose sensors may play a role in
detecting and countering severe glucose deficiency [68]. However, Levin et al. recently
showed there was no correlation between VMH glucose levels and spontaneous feeding
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[69]. It is therefore unlikely that VMH glucose sensors regulate meal-to-meal food intake, al‐
though it does not rule out a role for glucose sensors in the LH or other brain regions.
Figure 2. Schematic representation of a hypothalamic slice. Localization of the VMH and LH are indicated. GE and GI
neurons are activated or inactivated by a rise in glucose, respectively. The putative components responsible for glu‐
cose sensing in GE and GI are shown.
Glucose sensing neurons are those that alter their frequency of potential actions in response
to changes in interstitial glucose levels [60, 70]. There are mainly two neurons whose activity
is regulated by alterations in glucose levels [60]: Glucose-excited (GE) neurons that increase
their potential frequency in response to increases in interstitial glucose from 0.1 to 2.5 mM
glucose. The other kind of neurons (GI) are those that decrease their frequency of potential
actions when glucose rises. More recently [71], other neurons have been described that re‐
spond to an increase of more than 5 mM glucose. Thus, high GE (HGE) and high GI (HGI)
neurons increase or decrease their frequency of potential actions, respectively, in response to
increases in interstitial glucose from 5 to 20 mM, although these neurons are still not thor‐
oughly characterized, and there are doubts about their physiological significance. However,
it is important to consider that the interstitial brain glucose concentration is approximately
30% of the concentrations found in the blood. Thus, when the peripheral plasma glucose
concentration is 7.6 mM, the interstitial VMH glucose is only 2.5 mM [67]. Decreasing plas‐
ma glucose to 2–3 mM or increasing to 15 mM resulted in brain glucose levels of 0.16 mM
and 4.5 mM, respectively [67, 72]. Therefore, glucose concentrations found within the major‐
ity of the brain in vivo under physiological and pathophysiological conditions are within the
0.2 to 5 mM range [73-76], and it seems that the GE and GI neurons are mainly responsible
for glucose sensing, since it is unclear whether brain glucose levels ever exceed 5 mM in the
presence of an intact blood brain barrier. However, it should be noted that hyperglycemia
impairs the integrity of the blood brain barrier [77], raising the question of whether HGE
and HGI neurons could have a physiological significance in hyperglycemia-associated path‐
ology. Nevertheless, it seems that glucose sensing neurons could be functioning to protect
the brain against a severe energy deficit.
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The components responsible for glucose sensing in GE neurons seem to be shared with
those present in pancreatic beta-cells: GLUT2, as well as glucokinase. Furthermore, GE uses
the ATP-sensitive potassium (KATP) channel to sense glucose, as occurs in beta-cells. How‐
ever, while KATP channels are expressed in all GE neurons, only approximately half of
VMH GE neurons express glucokinase, and approximately 30% express GLUT2 [78].
Multiple subtypes of GE neurons may exist that use alternate glucose sensing strategies.
Thus, Claret et al. have shown that transgenic mice lacking the α2 subunit of AMPK, an im‐
portant cellular fuel gauge, also lack GE neurons in ARC [79]. However, other authors [80]
have shown that the acute pharmacological activation or inhibition of AMPK had no effect
on glucose sensing in VMH GE neurons.
GI neurons have similar components to GE and, therefore, to beta-cells in glucose sensing,
such as glucokinase [78, 81], as well as GLUT2 and GLUT4. However, the signal transduc‐
tion pathway, whereby changes in intracellular ATP alter the activity of GI neurons, is com‐
pletely different. In this case, the activation of α2AMPK by glucose mediates the activation
of VMH GI neurons, as described by Murphy et al. [82]. Hypothalamic α2AMPK is a key
kinase involved in the energy balance and is a target for a number of hormones and a trans‐
mitter that regulates the energy balance [83-88]. The pharmacological activation of hypo‐
thalamic AMPK increases food intake [89]. It is not therefore surprising that decreased
glucose activates AMPK in GI neurons.
4. AMPK, together with mTOR and its downstream target S6K1, integrate
nutrient and hormonal signals to maintain energy homeostasis
AMPK is a nutrient and energy sensor. AMPK senses cellular energy availability by detect‐
ing the AMP/ATP ratio. AMPK is activated in low energy states and promotes ATP-generat‐
ing catabolic pathways and inhibits anabolic reactions [90-92].
AMPK is a heterotrimeric complex that contains a catalytic α-subunit (α1 or α2) and two
regulatory subunits, β (β1, β2) and γ (γ1, γ2, γ3). The α-subunit contains a kinase domain.
The β-subunit contains the regions that permit interaction with other α and γ subunits and a
carbohydrate-binding domain that facilitates binding to glycogen. The γ subunit contains
four tandem repeats, which are four binding sites for adenosine derivates denominated as
CBS motifs (cystathionine β-synthase) [92, 93].
Different isoforms and the alternative splicing of some mRNAs encoding these subunits
give rise to a wide range of heterotrimeric combinations. The expression of the catalytic
subunits (α1 and α2) is also different. The α2 subunit expression has been found in pan‐
creatic  beta-cells,  neurons,  skeletal  muscle  and  the  heart.  The  liver  has  50%  of  each
AMPKα  isoform  (α1  and  α2),  while  adipose  tissue  expresses  higher  levels  of  the
AMPKα1 isoform [93].
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Figure 3. Schematic representation of AMPK’s subunits and its activation process. AMPK detects changes in the cellu‐
lar energy state that occur in response to nutrient variations or metabolic stress caused by changes in the AMP/ATP
ratio. The activation of AMPK triggers key enzymes of glucose metabolism and fatty acids. The long-term effect of
AMPK activation is the transcriptional control of the main elements involved in these metabolic pathways.
AMPK serine/threonine kinase activity is stimulated by the phosphorylation of the α-subu‐
nit on the Thr residue (Thr172). This activation process is regulated by several upstream kin‐
ases. The two main kinases in mammals are liver kinase B1 (LKB1), identified as a tumour-
suppressor, and the Ca2+/calmodulin-dependent protein kinase (mainly CaMKKβ) [92, 93].
AMPK activity is also allosterically regulated by AMP binding to the γ subunit (Figure 3).
Recent studies have found that AMP or ADP binding to the γ regulatory subunit protect the
activated phosphorylated form of AMPK [94, 95]. AMP, ADP and ATP bind the γ subunit
with similar affinity [94]. AMPK can be activated by increases in AMP and ADP according
to changes in the cellular levels of adenosine derivatives. LKB1 phosphorylates AMPK in al‐
most all tissues, while CaMKKβ plays an important role in neurons and T lymphocytes.
Other studies have suggested that a member of the MAPKKK family, TAK1 (transforming
growth factor β-activated kinase) could be an important AMPK upstream kinase in cardiac
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cells [96], and ATM (ataxia telangiectasia mutated) may also regulate the phosphorylation of
Thr172 [97]. The level of Thr172 phosphorylation depends also on the activity of protein
phosphatases [98, 99]. The effect of an increase in AMP inhibits phosphatase activity, and
considering that LKB1 is constitutively active [100], the response after a rise in AMP increas‐
es the phosphorylation of Thr172 and the activation of AMPK.
AMPK can detect changes in cellular energy state that occur in response to nutrient varia‐
tions. Any cellular or metabolic stress that reduces ATP production (e.g., heat shock, hypo‐
xia, ischemia, glucose deprivation) or accelerates ATP consumption (e.g., contraction of
skeletal muscle) will increase the ADP/ATP ratio, which will be amplified by the action of
adenylate kinase, resulting in increased AMP/ATP with the consequent activation of AMPK
(Figure 3). Once activated, AMPK first directly affects the activity of key enzymes of glucose
metabolism and fatty acids, and second, proceeds to the long-term regulation of the tran‐
scriptional control of the main elements involved in these metabolic pathways. The net re‐
sult of the activation of AMPK will restore the energy balance, inhibiting the anabolic
pathways responsible for the synthesis of macromolecules, such as proteins and glycogen,
and also of the following lipids: fatty acids, triglycerides and cholesterol, while activating
the catabolic pathways, such as the oxidation of fatty acids, glucose uptake and glycolysis
[101] (Figure 3).
The mTOR is a serine/threonine kinase that responds to nutrients and hormonal signals
[102-104].  mTOR forms two distinct  complexes with different  sensitivities  to  rapamycin:
mTORC1 and mTORC2. Both complexes contain mTOR, GβL (G-protein β-protein subu‐
nit-like),  mLST8 (mammalian lethal  with  SEC13 protein)  and deptor  (DEP domain con‐
taining  mTOR  interacting  protein)  [103,  105,  106].  This  complex,  along  with  raptor
(rapamycin-sensitive  adaptor  protein  of  mTOR) and PRAS40 (proline-rich  Akt  substrate
of  40  kDa)  forms  mTORC1,  which  is  rapamycin  and  nutrient  sensitive.  However,
mTORC2 comprises  mTOR,  GβL/mLST8 and deptor  together  with  rictor  (rapamycin-in‐
sensitive  companion  of  mTOR),  mSin  1  (mammalian  stress-activated  MAPK-interacting
protein 1)  and protor 1/2 (protein observed with rictor ½),  which is  insensitive to acute
rapamycin (Figure 4)
mTORC1 regulates metabolism and cell growth in response to several environmental sig‐
nals. The presence of amino acids, growth factors and mitogens stimulates mTORC1, which
promotes anabolic processes. The mTORC1 activity phosphorylates multiple substrates,
with S6K1 and the initiation factor 4E binding proteins (4E-BPs) being the best characterized
[106-108]. The activation of mTORC1 induces the dissociation of 4E-BP from the eukaryotic
translation initiation factor 4E (eIF4E), facilitating mRNA translation [109], and the activa‐
tion of S6K1 promotes protein synthesis. Moreover, the mTORC2 function is less well
known. It is known that mTORC2 phosphorylates Akt and appears to regulate mainly cell
proliferation and cell survival [110] (Figure 4)
The effect growth factors have on mTORC1 is mediated through phosphatidylinositol-3,4,5-
triphosphate kinase (PI3K) activation, the subsequent activation of phosphoinositide-de‐
pendent kinase (PDK1) and Akt. Once activated, Akt phosphorylates tuberous sclerosis
complex 2 (TSC2), suppressing the inhibitory effect of the TSC1-TSC2 complex in mTORC1.
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TSC2 functions as a GTPase-activating protein of Ras homolog enriched in brain (Rheb),
which is an mTORC1 activator. Mitogens activating the Ras/MAPK cascade also activate
mTORC1. ERK phosphorylates TSC2, inhibiting the TSC1/TSC2 complex and inducing
mTORC1 activity [111]. Raptor is additionally phosphorylated by ERK [112] (Figure 4)
Figure 4. Network of proteins involved in the AMPK/mTOR/S6K1 signalling pathway
mTORC1 is also stimulated by amino acids, especially leucine. This activation pathway is
independent of PI3K. The amino-acid regulation of mTOR needs rag GTPases and Rheb.
The detailed mechanism of activation is unknown. It has been suggested that rag GTPas‐
es  may  control  the  localization  of  mTOR  to  specific  vesicular  membranes  containing
Rheb-GTP [113].
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mTORC1 activity is inhibited in conditions of energy depletion coordinated with AMPK ac‐
tivity. An increase in AMP/ATP ratio activates AMPK, which phosphorylates the TSC2, and
this modification induces the concomitant inhibition of mTORC1 mediated by the TSC1-
TSC2 complex [114]. Furthermore, AMPK phosphorylates raptor in mTORC1, which down-
regulates this complex [115].
In addition, energy depletion inhibits mTORC1 by a mechanism that is independent of
AMPK activation. This effect is mediated by eliminating the GTP loading of Rheb [116].
4.1. Expression and regulation of these sensors in the VMH and LH
Studies in recent years have established a direct relationship between metabolic sensor ac‐
tivity in the hypothalamus and the regulation of food intake, body weight and energy ho‐
meostasis.
AMPK is broadly expressed throughout the brain. The α2 catalytic subunit is present with a
high distribution in neurons and activated astrocytes [117]. Hypothalamic AMPK has been
assumed to play a role in the central regulation of food intake and energy balance, whereby
fasting increases and re-feeding decreases AMPK activity in various hypothalamic nuclei.
Alterations of hypothalamic AMPK activity specifically affected α2AMPK and did not
change α1AMPK [88].
The hypothalamic AMPK role has been studied in vivo by the expression of AMPK mutants:
dominant negative AMPK (DN-AMPK) or constitutively active AMPK (CA-AMPK). The ex‐
pression of CA-AMPK in the medial hypothalamus by adenoviruses increased food intake
and body weight, whereas the expression of DN-AMPK inhibited them [88]. These altera‐
tions change the hypothalamic neuropeptide expression: the expression of CA-AMPK en‐
hances the effect of fasting, increasing the expression of NPY and AgRP in the ARC and the
melanin-concentrating hormone in the lateral hypothalamus, whereas the hypothalamic ex‐
pression of DN-AMPK decreases the expression of orexigenic neuropeptides NPY and
AgRP in ARC [88, 118].
mTORC1 is another metabolic sensor that plays an important role in the regulation of feed‐
ing behaviour and body weight in the hypothalamus [119, 120]. mTOR and its downstream
target S6K1 are widely distributed in the rat brain. The activated forms of mTOR and S6K1
are localized mainly in the paraventricular and arcuate nuclei [119], being co-localized in a
high percentage of orexigenic neurons that express AgRP/NPY and also in around half the
anorexigenic neurons that express POMC/CART in the arcuate nuclei [119].
mTORC1 activation in the rat hypothalamus decreases food intake and body weight. Similar
results were found by introducing constitutively active S6K1 mediated by adenovirus into
the mediobasal hypothalamus of the rat brain. By contrast, the injection of dominant-nega‐
tive S6K1 leads to an increase in food intake and body weight [121].
4.1.1. Nutrient regulation
Food intake leads to periods of fasting and feeding that are associated with substantial
changes in the level of available nutrients (e.g., glucose and amino acids) and accompanied
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by hormonal changes. Several studies describe the effect of glucose on both metabolic sen‐
sors, AMPK and mTOR, in hypothalamic areas. During fasting, the decrease in glucose con‐
centration activates AMPK. This period is also characterized by low levels of glucose and
amino acids, and the mTOR complex is kept inactive. The increase in glucose levels after
food intake decreases the activity of AMPK and, conversely, the activity of the mTOR/S6K1
pathway is stimulated by higher levels of glucose and amino acids.
Thus, Kim et al. reported that decreasing intracellular glucose through the supply of 2-deox‐
yglucose increases hypothalamic AMPK activity and food intake. By contrast, hyperglycae‐
mia decreases hypothalamic AMPK activity [122]. It was also observed that AMPK activity
is inhibited in arcuate, ventromedial, dorsomedial, paraventricular nuclei and the LH by
high glucose and re-feeding. [88]. Increases in α2-AMPK activities in arcuate-ventromedial
and paraventricular nuclei are also detected during insulin-induced hypoglycaemic in rats
[123]. However, fasted rats recorded a decrease in the number of hypothalamic cells express‐
ing mTOR and S6K1 activated forms specifically in the arcuate nucleus, with these changes
responding to the availability of nutrients [119]. Similar findings were subsequently con‐
firmed, also showing that the constitutive activation of S6K in the mediobasal hypothalamic
area protects against the harmful effects of a high-fat diet [121].
It has also been established that AMPK and mTOR are involved in the anorexigenic effect
induced by high protein diets. Thus, a high protein diet and the intracerebroventricular ad‐
ministration of leucine decreased AMPK phosphorylation in the rat hypothalamus [120].
The activation of hypothalamic mTORC1 is additionally produced by a high protein diet
and the intracerebroventricular administration of amino acids or leucine [119, 124].
4.1.2. Gut hormone regulation and signals from energy stores
The effects of glucose, amino acids and other nutrients are reinforced by the effects of intes‐
tinal peptides, as stated above. They are able to regulate food intake, energetic homeostasis
and body weight. The gastrointestinal tract responds to gut contents by secreting hormones,
which can serve to inform the CNS of nutrient status. Thus, circulating ghrelin, the only in‐
testinal peptide with orexigenic properties, is high in the period before a meal, and the level
declines an hour after eating [125]. Ghrelin stimulates food intake in lean and obese humans
[126]. In contrast, anorexigenic intestinal peptides as peptide YY (PYY), pancreatic polypep‐
tide (PP), GLP-1, oxyntomodulin and cholecystokinin are low during the fasting period, and
their level increases after a meal, and some of them are released proportionally to the
amount of calories ingested (Reviewed in [127]).
Other signals that inform the state of energy stores, such as leptin and insulin levels, are im‐
portant modulators of feeding behaviour. Insulin regulates the storage of nutrients and also
informs the brain about the energy balance [128]. Leptin is produced by adipose tissue and
informs the brain about the energy storage status [128].
We now know that the function of at least some of these peptides may be mediated by the
modulation of hypothalamic metabolic sensors. Thus, it has been reported that hypothala‐
mic AMPK activity is also regulated by several orexigenic and anorexigenic signals. Ghrelin,
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the intestinal peptide with orexigenic properties, activates AMPK and stimulates food intake
[87, 89]. By contrast, anorexigenic peptides such as leptin decrease AMPK activity in the
ARC and PVN [88, 89, 129]. However, leptin treatment increased mTOR and S6K1 hypo‐
thalamic activity [130].
It has recently been suggested that ghrelin activates AMPK in presynaptic neurons, induc‐
ing an increase in activity in NPY/AgRP neurons promoting sustained food intake, and this
signal stops after leptin is released by adipose tissue, signalling to stimulate POMC neurons
inhibiting feeding and also to inhibit the AMPK in the presynaptic neurons, inactivating the
release of NPY/AgRP [131].
Inoki et al. previously reported that the activation of AMPK induces the inhibition of mTOR
activity [114]. It has recently been posited that S6K phosphorylates α2 AMPK. This process
is necessary for the leptin effects on hypothalamic AMPK activity [132].
These findings indicate that hypothalamic AMPK and mTOR respond to changes in glu‐
cose and other nutrients in opposite ways, and their effects on the regulation of food in‐
take may overlap.
5. Modulation of AMPK and S6K by GLP-1/exendin-4 in these
hypothalamic areas
As indicated before, GLP-1 is able to induce several effects contributing to the control of
feeding behaviour. It inhibited gastric acid secretion and emptying, stimulated postprandial
insulin secretion and inhibited glucagon release. GLP-1 treatment to type 2 diabetic subjects
normalized the fasting levels of blood glucose and decreased postprandial glucose levels.
We have also reported that GLP-1 reduces glucose metabolism in the human hypothalamus
and brain stem [133].
In general, the brain activity of AMPK is activated by fasting and is inhibited by re-feeding
[88, 122, 123], but the effect of glucose on AMPK also regulates Ampk expression in VMH
[134]. Thus, fasting increased Ampk mRNA expression in the hypothalamus of rats, and the
ICV administration of GLP-1 reduced that effect [135].
The glucose effect on AMPK might be region-specific in hypothalamic areas that have oppo‐
site effects over the control of feeding behaviour. We have also reported, using rat hypo‐
thalamic slices, that high glucose levels decrease the expression of Ampk-α2 mRNA,
specifically in the LH, but not in the VMH [83]. The decrease in AMPKα2 expression in re‐
sponse to high glucose levels was reversed by the presence of GLP-1 [83]. Sanz et al. have
also reported a different response to glucose in the VMH and LH [136, 137]. The distinctive
response in the LH compared to the VMH may be explained by the different role these two
areas have in the control of food intake.
Results obtained from in vivo studies conducted on lean and obese Zucker rats showed that
the effects fasting and re-feeding have on the activity of AMPK and S6K in the areas in‐
volved in the control of feeding are modulated by exendin-4 treatment [83].
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It has been previously reported that the anorexigenic effects produced by the intraperitoneal
administration of exendin-4 led to a reduction in food intake and increased the period be‐
tween meals [138]. Additionally, the peripheral administration of exendin-4 and liraglutide
regulates food intake by activating the GLP-1 receptors expressed on both vagal afferents
and CNS [139]. Recent studies conducted within our group [83] have focused on clarifying
the coordinated effects of fasting, re-feeding and exendin-4 administration on the activity of
AMPK and S6K in the VMH and LH. The results of these studies show that fasting increases
hypothalamic AMPK activity in both areas in lean Zucker rats. However, the subcutaneous
administration of exendin-4 over the last hour reversed this effect, whereas exendin-4 acti‐
vated AMPK in animals re-fed for two hours when AMPK activity was markedly inhibited.
The activation degree of AMPK after four hours of re-feeding differed in both areas. Thus,
the activation level of AMPK in the VMH was similar to fasted rats. However, AMPK activi‐
ty in the LH was still low, and exendin-4 treatment decreased AMPK activity in the VMH,
whereas no significant effect was detected in the LH (Figure 5).
Anorexic peptides also regulate the mTOR/S6K1 pathway in hypothalamic areas. Insulin
and leptin increases the activated forms of S6K [119]. The administration of exendin-4 also
regulates S6K activity and the effect is dependent on the activation status of S6K, as occur‐
red with AMPK. We thus found that S6K activation peaked in animals re-fed for four hours.
However, the administration of exendin-4 strongly stimulated S6K activity in animals re-fed
for two hours. In contrast, exendin-4 decreased S6K activity in the VMH of lean rats re-fed
for four hours [83] (Figure 5).
The use of rat organotypic hypothalamic slices confirmed that AMPK activity at low glucose
concentrations was stimulated, and S6K activity was maintained with minimal activation
[83]. GLP-1 treatment reversed the effect of glucose on AMPK and did not modify S6K activ‐
ity in the VMH and LH. High levels of glucose stimulated S6K activity in both nuclei, and
the presence of GLP-1 reversed such activation. Similar results were found using hypothala‐
mic GT1-7 and neuroblastoma N2A cell lines [83]. The metabolic sensors in these cells re‐
spond to glucose as described above, and GLP-1 treatment reversed the glucose effects [83].
The effect of GLP-1 on AMPK activity was also reported in other brain areas. Thus, GLP-1R
activation in hindbrain suppressed food intake, and that effect is accompanied by the sup‐
pression of AMPK activity [140].
The complexities of the regulation of hypothalamic AMPK activity have previously been de‐
scribed for some hormones. Thus, the cocaine-and amphetamine-regulated transcript
(CART) has been reported to have an anorexic effect after intracerebroventricular adminis‐
tration [141], while CART injected directly into the paraventricular or arcuate nucleus of
fasted rats increases food intake [142]. Likewise, differences in the effect of regulatory pepti‐
des on AMPK as a function of nutritional status have been previously described. Ghrelin or
cannabinoids have ad libitum effects [143], whereas leptin [88] and adiponectin [144] only
have an effect after variable periods of fasting or re-feeding.
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Figure 5. Effects of exendin-4 administration in fasted or re-fed lean rats on the activity of AMPK and S6K. Lean Zucker
rats were fasted or re-fed for two or four hours. In some cases, the GLP-1 analogue exendin-4 (100 nM) was adminis‐
trated. The activation states of AMPK and S6K were determined by quantifying phospho-specific forms in VMH and LH
areas.
6. GLP-1/exendin-4 as a compensator of the disturbances in AMPK and
S6K activities occurring in obesity
In obesity, the elevated levels of nutrients and hormonal modifications alter the activity of
hypothalamic metabolic sensors. Thus, diet-induced obesity reduced hypothalamic AMPK
activity [145]. The GLP-1 receptor agonist exendin-4 is one of the agents used in the treat‐
ment of type 2 diabetes [146] and is a long-acting receptor agonist of GLP-1 that also produ‐
ces weight loss [147-149].
The obese Zucker (fa/fa) rat provides a well-established animal model of insulin resistance
and genetic obesity and, in comparison with lean Zucker rats, manifests hyperinsulinemia
and hyperlipidemia. We have previously noted that the peripheral long-term subcutaneous
administration of exendin-4 decreased food intake and induced weight loss in both obese
and lean control Zucker rats [15].
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Zucker rats have been used to analyze the exendin-4 effect on the activity of AMPK and S6K
in the VMH and LH areas [83]. The results obtained showed that AMPK activity was lower
in the obese than in the lean Zucker rats in both areas. Interestingly, the effect of exendin-4
administration on fasted obese Zucker rats was different compared to the lean rats. The ab‐
sence of exendin-4 effect in obese rats maintains AMPK activity at a level of activation simi‐
lar to the lean animals after the administration of exendin-4 [83] (Figure 5).
These results suggest that GLP-1/exendin-4 might compensate for the alterations in AMPK,
activity produced either by oscillations in glucose levels or by pathologies such as obesity or
episodes of hyperinsulinemia (Figure 5, 6).
Figure 6. Effects of exendin-4 administration in fasted or re-fed obese rats on the activity of AMPK and S6K. Lean
Zucker rats were fasted or re-fed for two or four hours. In some cases, the GLP-1 analogue exendin-4 (100 nM) was
administrated. The activation states of AMPK and S6K were determined by quantifying phospho-specific forms in the
VMH and LH areas.
Another difference in the level of activation of AMPK between obese and lean Zucker rats
was observed after re-feeding for four hours. The AMPK activity in the LH was higher in
obese compared to lean animals (Figure 5, 6).
After two hours of re-feeding, exendin-4 treatment increased S6K activity in the VMH and
LH in obese rats. Nevertheless, the effect of exendin-4 on S6K activity in the VMH differed
between obese and lean rats. Exendin-4 administration did not modify S6K activity in the
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LH of lean and obese rats after four hours of re-feeding, whereas exendin-4 reduced S6K ac‐
tivity in the VMH of lean Zucker rats but not in their obese counterparts [83].
The prolonged activation of hypothalamic S6K inhibits insulin signalling and contributes to
hepatic insulin resistance [150], suggesting that hypothalamic S6K activation would be in‐
volved in the pathogenesis of diet-induced hepatic insulin resistance. Our data indicate that
S6K activity in the presence of exendin-4 could be decreased when this protein is maximally
activated. This suggests that exendin-4 treatment in diabetic subjects could also improve
hepatic insulin resistance.
7. Conclusions
We have reported here some of the many actions of GLP-1, such as, its role as an incretin
hormone and controlling food intake. Accordingly, we have reviewed the importance of hy‐
pothalamic areas in the control of food intake, such as, for example, the ventromedial and
lateral hypothalamus. In parallel, the function of AMPK and the mTOR/S6K pathway has
been studied in those areas. Likewise, we have explored the coordinated response of hypo‐
thalamic AMPK and S6K to alterations in nutritional status and energy storage. Our results
have revealed both the activation of AMPK and S6K in the VMH and LH in response to
changes in glucose concentration or nutritional state, and that GLP-1/exendin-4 acts by
counteracting the activation/inactivation of these kinases and contributing to the balance of
proper AMPK and S6K activation. It therefore seems that GLP-1/exendin-4 might be acting
in the VMH and LH, interacting with the AMPK/S6K signalling pathways, and modulating
the activation status of AMPK and S6K in response to nutrient fluctuations. Likewise,
GLP-1/exendin-4 would contribute to the normalization of the altered levels of these kinases
in pathophysiological states such as obesity, for example.
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